More changes in cancer test services as Genzyme steps up
This article was originally published in Clinica
Executive Summary
Genzyme has emerged as the lead bidder for Impath's cancer diagnostic services business, which filed for Chapter 11 bankruptcy protection last September. Genzyme, which launched a bid for cancer drug business Ilex Oncology last week, has put $215m in cash on the table for Impath Physician Services.